Physician profile
Christopher C Smith
NPI 1548206725
$3,504.16
in general payments reported to CMS, 2019-2025
21 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $276 · 2023: $855 · 2024: $836 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $725.24 | 2021-2025 | |
| Amgen INC. | $467.53 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $450.23 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.62 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $294.47 | 2021-2025 | Farxiga, Breztri, Andexxa |
| Philips North America LLC | $286.01 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Pfizer INC. | $190.59 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $183.65 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $150.32 | 2023-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $130.02 | 2023 | Cardiomems |
| Merck Sharp & Dohme LLC | $69.31 | 2022-2023 | Verquvo |
| Esperion Therapeutics, INC. | $56.64 | 2021-2023 | Nexletol |
| Kiniksa Pharmaceuticals, Ltd. | $37.71 | 2023 | Arcalyst |
| Boston Scientific Corporation | $30.21 | 2021 | |
| Abbvie INC. | $25.32 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25.26 | 2022-2023 | Rybelsus, Ozempic |
| Atricure, INC. | $19.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.96 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $16.05 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.08 | 2024 | |
| Kestra Medical Technology Services, INC. | $13.38 | 2023 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.